Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985946 · ClinicalTrials.gov registry record · Phase 2
Study of Panobinostat in Patients With Neuroendocrine Tumors
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00985946 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 15 participants.
The verdict
NCT00985946, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This summary will use Panobinostat (LBH589) in patients with neuroendocrine tumors to see how the patient's tumor responds to panobinostat. Additionally, this study will examine how long it takes neuroendocrine tumor patient's cancer to progress while taking the drug and examine the overall survival of patients using panobinostat. Also, the study will examine the toxicity and tolerability of panobinostat in the patient population. Finally, this study will look at the effect of panobinostat on Notch 1 signaling before and after treatment with panobinostat.
Interventions
- DRUG panobinostat (LBH589)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985946
The ClinicalTrials.gov registry entry for NCT00985946 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which panobinostat (LBH589) is the first listed.
NCT00985946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00985946 about?
NCT00985946 is a clinical study titled "Study of Panobinostat in Patients With Neuroendocrine Tumors". This summary will use Panobinostat (LBH589) in patients with neuroendocrine tumors to see how the patient's tumor responds to panobinostat. Additionally, this study will examine how long it takes neuroendocrine tumor patient's cancer to progress while taking the drug and examine the overall survival...
What is the current status of trial NCT00985946?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00985946?
The interventions under investigation include: panobinostat (LBH589) (DRUG).
Who is sponsoring clinical trial NCT00985946?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.